Safety and feasibility of estrogen receptor-? targeted phytoSERM formulation for menopausal symptoms: phase 1b/2a randomized clinical trial.

Schneider LS, Hernandez G, Zhao L, Franke AA, Chen YL, Pawluczyk S, Mack WJ, Brinton RD. Safety and feasibility of estrogen receptor-? targeted phytoSERM formulation for menopausal symptoms: phase 1b/2a randomized clinical trial. Menopause. 2019 08; 26(8):874-884.

View in: PubMed

subject areas

Cognition
Cross-Over Studies
Dose-Response Relationship, Drug
Double-Blind Method
Drug Therapy, Combination
Estrogen Receptor beta
Female
Genistein
Hot Flashes
Humans
Isoflavones
Middle Aged
Perimenopause

authors with profiles

Adrian Franke, PhD

RCMI CC is supported by the National Institute on Minority Health and Health Disparities, National Institutes of Health (NIH), through Grant Number U24MD015970. The contents of this site are solely the responsibility of the authors and do not necessarily represent the official views of the NIH

For technical support please contact support